Celularity Inc has filed an amended annual report for the fiscal year ending December 31, 2025. This update, submitted on October 20, 2026, is significant for the company as it seeks to ensure accurate and transparent financial reporting.
Celularity Inc, classified under the SIC code 2834 for Pharmaceutical Preparations, is a company focused on developing innovative therapies using cellular technology. The firm trades on the Nasdaq under the ticker CELU and operates as a smaller reporting company based in Florham Park, New Jersey.
The filing indicates that this amendment is part of the company's commitment to uphold regulatory compliance and provide stakeholders with the most accurate financial information. The filing states, "Amendment No. 1 to Form 10-K/A" with a focus on the fiscal year 2025, emphasizing the importance of updated disclosures.
This amendment may affect various stakeholders, including investors, analysts, and regulatory bodies, as accurate financial reporting is essential for maintaining market trust and compliance with SEC regulations.
What's next for Celularity Inc remains unclear, as the filing does not specify any further actions or upcoming disclosures related to this amendment.
Company Overview
Celularity Inc. was formerly known as GX Acquisition Corp. following a name change on September 12, 2018. The company is incorporated in Delaware and operates primarily in the pharmaceutical preparations sector, focusing on cellular technology for therapeutic applications.
Contact Information
The company's principal office is located at 170 Park Ave, Florham Park, NJ, 07932. For inquiries, stakeholders can reach the company at (908) 768-2170.
Filing Details
This amended filing, identified as Amendment No. 1 to Form 10-K/A, is categorized under the SEC Act of 1934 and is assigned the SEC file number 001-38914. The filing is part of Celularity's ongoing efforts to maintain compliance with regulatory requirements.
Regulatory Status
Celularity Inc. is classified as a smaller reporting company and is not considered a well-known seasoned issuer as defined in Rule 405 of the Securities Act. The company has confirmed that it is not required to file reports pursuant to Section 13 or 15(d) of the Act, indicating its compliance with the necessary regulatory frameworks.
Stock Information
Celularity's Class A common stock, with a par value of $0.0001 per share, is traded under the ticker symbol CELU on The Nasdaq Stock Market LLC. The filing does not provide specific information regarding the number of shares outstanding or recent trading activity.
Future Disclosures
While this amendment emphasizes regulatory compliance, the filing does not outline any specific future plans, initiatives, or upcoming disclosures that Celularity Inc. may pursue following this amendment.